Dossier
CAP-002
Coverage of CAP-002 in the Nexus archive.
- STAT+: Capsida says it still doesn’t know what caused gene therapy death
Capsida Biotherapeutics is investigating the death of a child in a gene therapy trial, but efforts have been hindered by the hospital's refusal to share tissue samples from an autopsy. The therapy, CAP-002, was designed to deliver genes deep into the brain. The company still has no answers as to what caused the death.